OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats
Silje Skrede, Johan Fernø, María J. Vázquez, et al.
The International Journal of Neuropsychopharmacology (2011) Vol. 15, Iss. 2, pp. 163-179
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis
Cherrie Galletly, Debra L. Foley, Anna Waterreus, et al.
Australian & New Zealand Journal of Psychiatry (2012) Vol. 46, Iss. 8, pp. 753-761
Closed Access | Times Cited: 194

Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system
Joanne Y.T. Leung, Alasdair M. Barr, Ric M. Procyshyn, et al.
Pharmacology & Therapeutics (2012) Vol. 135, Iss. 2, pp. 113-122
Closed Access | Times Cited: 148

Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation
Johan Fernø, Luis Varela, Silje Skrede, et al.
PLoS ONE (2011) Vol. 6, Iss. 6, pp. e20571-e20571
Open Access | Times Cited: 122

The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain
Meng Xiao He, Chao Deng, Xu‐Feng Huang
CNS Drugs (2013) Vol. 27, Iss. 6, pp. 423-434
Closed Access | Times Cited: 105

Atypical antipsychotic drugs cause abnormal glucose and lipid metabolism independent of weight gain
Ye Yang, Renrong Wu
European Archives of Psychiatry and Clinical Neuroscience (2025)
Closed Access | Times Cited: 1

Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro
Alberto Canfrán‐Duque, María E. Casado, Óscar Pastor, et al.
Journal of Lipid Research (2012) Vol. 54, Iss. 2, pp. 310-324
Open Access | Times Cited: 98

Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms
Pedro Gonçalves, João R. Araújo, Fátima Martel
European Neuropsychopharmacology (2014) Vol. 25, Iss. 1, pp. 1-16
Closed Access | Times Cited: 93

Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
Yueshan Hu, Alan J. Young, Erik A. Ehli, et al.
PLoS ONE (2014) Vol. 9, Iss. 3, pp. e93310-e93310
Open Access | Times Cited: 73

Effect of lysosomotropic molecules on cellular homeostasis
Omer F. Kuzu, Mesut Toprak, Mohammad A. Noory, et al.
Pharmacological Research (2016) Vol. 117, pp. 177-184
Closed Access | Times Cited: 70

A Focused Review of the Metabolic Side-Effects of Clozapine
Jessica W. Y. Yuen, David D. Kim, Ric M. Procyshyn, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 53

Berberine Alleviates Olanzapine-Induced Adipogenesis via the AMPKα–SREBP Pathway in 3T3-L1 Cells
Yan-Jie Li, Xiaomin Zhao, Xiyu Feng, et al.
International Journal of Molecular Sciences (2016) Vol. 17, Iss. 11, pp. 1865-1865
Open Access | Times Cited: 50

Antipsychotics Promote Metabolic Disorders Disrupting Cellular Lipid Metabolism and Trafficking
Chiara Vantaggiato, Elena Panzeri, Andrea Citterio, et al.
Trends in Endocrinology and Metabolism (2019) Vol. 30, Iss. 3, pp. 189-210
Closed Access | Times Cited: 44

The role of ghrelin signalling in second-generation antipsychotic-induced weight gain
Qingsheng Zhang, Chao Deng, Xu‐Feng Huang
Psychoneuroendocrinology (2013) Vol. 38, Iss. 11, pp. 2423-2438
Closed Access | Times Cited: 54

Olanzapine Activates Hepatic Mammalian Target of Rapamycin: New Mechanistic Insight into Metabolic Dysregulation with Atypical Antipsychotic Drugs
Robin Schmidt, Jenny D. Jokinen, Veronica Massey, et al.
Journal of Pharmacology and Experimental Therapeutics (2013) Vol. 347, Iss. 1, pp. 126-135
Open Access | Times Cited: 54

Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects
Silje Skrede, Luís Martins, Rolf K. Berge, et al.
The International Journal of Neuropsychopharmacology (2013) Vol. 17, Iss. 01, pp. 91-104
Open Access | Times Cited: 52

Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats
Heidi N. Boyda, Alfredo Ramos‐Miguel, Ric M. Procyshyn, et al.
The International Journal of Neuropsychopharmacology (2013) Vol. 17, Iss. 01, pp. 77-90
Open Access | Times Cited: 48

Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia
Hu Yan, Jindong Chen, Xiaoyan Zheng
Psychopharmacology (2013) Vol. 229, Iss. 1, pp. 1-7
Closed Access | Times Cited: 46

A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation
Rune A. Kroken, Else‐Marie Løberg, Tore Drønen, et al.
Frontiers in Psychiatry (2014) Vol. 5
Open Access | Times Cited: 46

Curcumin Activates AMPK Pathway and Regulates Lipid Metabolism in Rats Following Prolonged Clozapine Exposure
Zhen Liu, Changmeng Cui, Pengfei Xu, et al.
Frontiers in Neuroscience (2017) Vol. 11
Open Access | Times Cited: 45

Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways
Xuemei Liu, Jiamei Lian, Changhua Hu, et al.
Pharmacological Research (2015) Vol. 100, pp. 36-46
Closed Access | Times Cited: 42

Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment
Vidar M. Steen, Silje Skrede, Tatiana Polushina, et al.
European Neuropsychopharmacology (2016) Vol. 27, Iss. 6, pp. 589-598
Closed Access | Times Cited: 42

Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats
Paolo Lazzari, Valeria Serra, S. Marcello, et al.
European Neuropsychopharmacology (2017) Vol. 27, Iss. 7, pp. 667-678
Closed Access | Times Cited: 41

Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients
Julia Lappin, Marlene Wijaya, Andrew Watkins, et al.
Schizophrenia Research (2018) Vol. 199, pp. 367-373
Closed Access | Times Cited: 41

Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism
L Castellani, Kenya A. Costa-Dookhan, William Brett McIntyre, et al.
Journal of Psychiatry and Brain Science (2019)
Open Access | Times Cited: 40

Antipsychotic-Induced Alterations in Lipid Turnover
Sandra Pereira, Emily Au, Sri Mahavir Agarwal, et al.
Endocrinology (2023) Vol. 164, Iss. 4
Open Access | Times Cited: 11

Page 1 - Next Page

Scroll to top